edotreotide has been researched along with Brain Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, JC; Bröcker, EB; Buck, AK; Buder, K; Goebeler, M; Herrmann, K; Kreissl, MC; Lapa, C; Schirbel, A; Schnack, A | 1 |
| Bisdas, S; Boss, A; Claussen, CD; Ernemann, U; Hofmann, M; Kolb, A; Pfannenberg, C; Pichler, BJ; Reimold, M; Stegger, L | 1 |
| Freitag, P; Gratzl, O; Hausmann, O; Jermann, E; Mäcke, HR; Merlo, A; Müller-Brand, J; Otte, A; Reubi, JC; Steiner, P; Wasner, M | 1 |
| Eichhorn, K; Freitag, P; Hofer, S; Maecke, H; Merlo, A; Muller-Brand, J; Reubi, JC | 1 |
| Eichhorn, K; Freitag, P; Gratzl, O; Hofer, S; Maecke, R; Merlo, A; Mueller-Brand, J; Probst, A; Reubi, JC; Schumacher, T; Wasner, M; Zimmerer, S | 1 |
2 trial(s) available for edotreotide and Brain Neoplasms
| Article | Year |
|---|---|
Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
Topics: Adult; Astrocytoma; Binding, Competitive; Brain Edema; Brain Neoplasms; Diffusion; Disease Progression; Female; Glioblastoma; Glioma; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Proteins; Octreotide; Oligodendroglioma; Pilot Projects; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Stereotaxic Techniques; Tissue Distribution; Ytterbium | 1999 |
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioma; Humans; Injections, Intralesional; Magnetic Resonance Imaging; Male; Middle Aged; Octreotide; Pilot Projects; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Receptors, Somatostatin; Sensitivity and Specificity; Treatment Outcome; World Health Organization; Yttrium Radioisotopes | 2002 |
3 other study(ies) available for edotreotide and Brain Neoplasms
| Article | Year |
|---|---|
Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Merkel Cell; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Molecular Imaging; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tomography, X-Ray Computed | 2014 |
Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT.
Topics: Adult; Aged; Brain Neoplasms; Data Interpretation, Statistical; Female; Gallium Radioisotopes; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Methionine; Middle Aged; Octreotide; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed | 2010 |
Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC).
Topics: Adult; Astrocytoma; Brachytherapy; Brain; Brain Neoplasms; Humans; Magnetic Resonance Imaging; Male; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage | 2001 |